Record-Setting US$200M Series A Round for Esco Lifesciences

Esco Lifesciences announced the close of a US$200 million Series A and Crossover round last May 26, 2021. The financing was led by Vivo Capital and Novo Holding A/S, leading healthcare and life science investment companies, accompanied by new investors including China Investment Corporation and EDBI to name a few.

As a leading provider of life science tools and services, Esco Lifesciences benefits from the growth of the global healthcare and biopharma industries. Esco Lifesciences, being headquartered in Singapore, is the nexus between East and West which enables the company to bring its products and services all over the world.

To learn more about Esco’s record-setting Series A funding, visit:
https://www.group.escolifesciences.com/esco-lifesciences-group-news-center/esco-lifesciences-closes-a-record-setting-us%24200m-series-a-round-led-by-vivo-capital-and-novo-holdings